View : 279 Download: 0

Efficacy of thrombus aspiration in cardiogenic shock complicating acute myocardial infarction and high thrombus burden; [Eficacia de la tromboaspiración en pacientes con shock cardiogénico secundario a infarto agudo de miocardio y alta carga trombótica]

Title
Efficacy of thrombus aspiration in cardiogenic shock complicating acute myocardial infarction and high thrombus burden; [Eficacia de la tromboaspiración en pacientes con shock cardiogénico secundario a infarto agudo de miocardio y alta carga trombótica]
Authors
Kwon W.Choi K.H.Yang J.H.Chung Y.J.Park T.K.Lee J.M.Song Y.B.Hahn J.-Y.Choi S.-H.Ahn C.-M.Yu C.W.Park I.H.Jang W.J.Kim H.-J.Bae J.-W.Kwon S.U.Lee H.-J.Lee W.S.Jeong J.-O.Park S.-D.Gwon H.-C.
Ewha Authors
장우진
SCOPUS Author ID
장우진scopusscopus
Issue Date
2023
Journal Title
Revista Espanola de Cardiologia
ISSN
3008-8932JCR Link
Citation
Revista Espanola de Cardiologia vol. 76, no. 9, pp. 719 - 728
Keywords
Cardiogenic shockCoronary thrombosisMyocardial infarctionThrombectomy
Publisher
Ediciones Doyma, S.L.
Indexed
SCOPUS scopus
Document Type
Article
Abstract
Introduction and objectives: Current guidelines do not recommend routine thrombus aspiration in acute myocardial infarction (AMI) because no benefits were observed in previous randomized trials. However, there are limited data in cardiogenic shock (CS) complicating AMI. Methods: We included 575 patients with AMI complicated by CS. The participants were stratified into the TA and no-TA groups based on use of TA. The primary outcome was a composite of 6-month all-cause death or heart failure rehospitalization. The efficacy of TA was additionally assessed based on thrombus burden (grade I-IV vs V). Results: No significant difference was found in in-hospital death (28.9% vs 33.5%; P =.28), or 6-month death, or heart failure rehospitalization (32.4% vs 39.4%; HRadj: 0.80; 95%CI, 0.59-1.09; P =.16) between the TA and no-TA groups. However, in 368 patients with a higher thrombus burden (grade V), the TA group had a significantly lower risk of 6-month all-cause death or heart failure rehospitalization than the no-TA group (33.4% vs 46.3%; HRadj: 0.59; 95%CI, 0.41-0.85; P =.004), with significant interaction between thrombus burden and use of TA for primary outcome (adjusted Pint =.03). Conclusions: Routine use of TA did not reduce short- and mid-term adverse clinical outcomes in patients with AMI complicated by CS. However, in select patients with a high thrombus burden, the use of TA might be associated with improved clinical outcomes. The study was registered at ClinicalTrials.gov (Identifier: NCT02985008). © 2023 Sociedad Española de Cardiología
DOI
10.1016/j.recesp.2023.01.013
Appears in Collections:
의료원 > 의료원 > Journal papers
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

BROWSE